RS65652B1 - Postupci lečenja bolesti u kojima je dejstvo il-13 štetno pomoću antitela protiv il-13 - Google Patents
Postupci lečenja bolesti u kojima je dejstvo il-13 štetno pomoću antitela protiv il-13Info
- Publication number
- RS65652B1 RS65652B1 RS20240677A RSP20240677A RS65652B1 RS 65652 B1 RS65652 B1 RS 65652B1 RS 20240677 A RS20240677 A RS 20240677A RS P20240677 A RSP20240677 A RS P20240677A RS 65652 B1 RS65652 B1 RS 65652B1
- Authority
- RS
- Serbia
- Prior art keywords
- detrimental
- antibodies
- diseases
- activity
- treatment
- Prior art date
Links
- 230000001627 detrimental effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328539P | 2016-04-27 | 2016-04-27 | |
| EP17790401.8A EP3448391B1 (en) | 2016-04-27 | 2017-04-27 | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| PCT/US2017/029768 WO2017189805A1 (en) | 2016-04-27 | 2017-04-27 | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65652B1 true RS65652B1 (sr) | 2024-07-31 |
Family
ID=60160091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240677A RS65652B1 (sr) | 2016-04-27 | 2017-04-27 | Postupci lečenja bolesti u kojima je dejstvo il-13 štetno pomoću antitela protiv il-13 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11390669B2 (sr) |
| EP (2) | EP3448391B1 (sr) |
| JP (4) | JP6871948B2 (sr) |
| KR (3) | KR20220147722A (sr) |
| CN (2) | CN114617962A (sr) |
| AU (4) | AU2017258097B2 (sr) |
| BR (1) | BR112018072263A2 (sr) |
| CA (1) | CA3021334C (sr) |
| DK (1) | DK3448391T3 (sr) |
| EA (2) | EA037960B1 (sr) |
| FI (1) | FI3448391T3 (sr) |
| HR (1) | HRP20240846T1 (sr) |
| IL (2) | IL297519B2 (sr) |
| LT (1) | LT3448391T (sr) |
| MX (2) | MX2018013172A (sr) |
| PL (1) | PL3448391T3 (sr) |
| PT (1) | PT3448391T (sr) |
| RS (1) | RS65652B1 (sr) |
| SG (1) | SG11201809253RA (sr) |
| SI (1) | SI3448391T1 (sr) |
| WO (1) | WO2017189805A1 (sr) |
| ZA (2) | ZA201807174B (sr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3021334C (en) * | 2016-04-27 | 2022-11-29 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| US11136387B2 (en) | 2016-05-18 | 2021-10-05 | Shanghai Pharmaexplorer Co., Ltd. | IL-13 antibody and preparation method and use thereof |
| TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| KR20200134233A (ko) * | 2018-02-21 | 2020-12-01 | 아데어 파마슈티컬스 유에스, 엘.피. | 호산구성 식도염을 관리하는 방법 |
| WO2021237110A1 (en) * | 2020-05-22 | 2021-11-25 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| AU4434585A (en) | 1985-03-30 | 1986-10-23 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| PL188192B1 (pl) | 1996-02-09 | 2004-12-31 | Abbott Lab Bermuda Ltd | Izolowane ludzkie przeciwciało albo jego część wiążąca antygen, rekombinowane ludzkie przeciwciało albo jego część wiążąca antygen, kompozycje farmaceutyczne, izolowane kwasy nukleinowe, rekombinowany wektor ekspresyjny, komórka gospodarza, sposób syntetyzowania przeciwciała ludzkiego, które wiąże ludzki TNFalfa, sposób hamowania aktywności ludzkiego TNFalfa in vitro, przeciwciało albo jego częśćwiążąca antygen, zastosowanie przeciwciała albo jego części wiążącej antygen |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| AU2001259432B2 (en) | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| JP4063213B2 (ja) | 2003-12-09 | 2008-03-19 | カシオ計算機株式会社 | 光源装置及びそれを備えたプロジェクタ |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US8324192B2 (en) * | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| EP2064336B1 (en) * | 2006-09-08 | 2017-12-27 | AbbVie Bahamas Ltd. | Interleukin -13 binding proteins |
| JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
| EP2491055A2 (en) * | 2009-10-20 | 2012-08-29 | Abbott Laboratories | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
| PT2624865T (pt) | 2010-10-06 | 2018-11-05 | Regeneron Pharma | Formulações estabilizadas que contêm anticorpos anti-recetor de interleucina-4 (il-4r) |
| MX352789B (es) | 2010-12-16 | 2017-12-08 | Genentech Inc | Anticuerpo anti-il-13 para usarse en tratar un asma o un trastorno respiratorio. |
| US9928344B2 (en) | 2011-06-21 | 2018-03-27 | Children's Hospital Medical Center | Diagnostic methods of eosinophilic esophagitis |
| WO2012178188A2 (en) | 2011-06-23 | 2012-12-27 | Children's Hospital Medical Center | Molecular diagnostic panel of eosinophilic gastrointestinal disorders |
| CA2841970A1 (en) | 2011-07-13 | 2013-01-17 | Abbvie Inc. | Methods and compositions for treating asthma using anti-il-13 antibodies |
| JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
| TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
| TWI634900B (zh) * | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
| WO2015061441A1 (en) * | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
| US10176301B2 (en) | 2014-09-11 | 2019-01-08 | Meritage Pharma, Inc. | Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis |
| CA3021334C (en) | 2016-04-27 | 2022-11-29 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2017
- 2017-04-27 CA CA3021334A patent/CA3021334C/en active Active
- 2017-04-27 CN CN202210154170.XA patent/CN114617962A/zh active Pending
- 2017-04-27 IL IL297519A patent/IL297519B2/en unknown
- 2017-04-27 HR HRP20240846TT patent/HRP20240846T1/hr unknown
- 2017-04-27 PT PT177904018T patent/PT3448391T/pt unknown
- 2017-04-27 WO PCT/US2017/029768 patent/WO2017189805A1/en active Application Filing
- 2017-04-27 EA EA201892409A patent/EA037960B1/ru unknown
- 2017-04-27 MX MX2018013172A patent/MX2018013172A/es unknown
- 2017-04-27 RS RS20240677A patent/RS65652B1/sr unknown
- 2017-04-27 KR KR1020227036943A patent/KR20220147722A/ko not_active IP Right Cessation
- 2017-04-27 EP EP17790401.8A patent/EP3448391B1/en active Active
- 2017-04-27 SG SG11201809253RA patent/SG11201809253RA/en unknown
- 2017-04-27 EP EP23191176.9A patent/EP4276108A3/en active Pending
- 2017-04-27 CN CN201780040303.8A patent/CN109562115A/zh active Pending
- 2017-04-27 DK DK17790401.8T patent/DK3448391T3/da active
- 2017-04-27 LT LTEPPCT/US2017/029768T patent/LT3448391T/lt unknown
- 2017-04-27 BR BR112018072263-4A patent/BR112018072263A2/pt active Search and Examination
- 2017-04-27 US US16/092,943 patent/US11390669B2/en active Active
- 2017-04-27 AU AU2017258097A patent/AU2017258097B2/en active Active
- 2017-04-27 JP JP2018556362A patent/JP6871948B2/ja active Active
- 2017-04-27 EA EA202190162A patent/EA202190162A3/ru unknown
- 2017-04-27 SI SI201731529T patent/SI3448391T1/sl unknown
- 2017-04-27 PL PL17790401.8T patent/PL3448391T3/pl unknown
- 2017-04-27 KR KR1020247011874A patent/KR20240052871A/ko active Search and Examination
- 2017-04-27 KR KR1020187034419A patent/KR102460040B1/ko active IP Right Grant
- 2017-04-27 FI FIEP17790401.8T patent/FI3448391T3/fi active
-
2018
- 2018-10-17 IL IL262441A patent/IL262441B2/en unknown
- 2018-10-26 MX MX2022008255A patent/MX2022008255A/es unknown
- 2018-10-26 ZA ZA2018/07174A patent/ZA201807174B/en unknown
-
2019
- 2019-12-06 AU AU2019275659A patent/AU2019275659B2/en active Active
-
2020
- 2020-01-24 ZA ZA2020/00478A patent/ZA202000478B/en unknown
- 2020-11-19 JP JP2020192246A patent/JP7124040B2/ja active Active
-
2021
- 2021-05-24 AU AU2021203358A patent/AU2021203358B2/en active Active
-
2022
- 2022-05-10 US US17/740,988 patent/US20220281968A1/en active Pending
- 2022-08-09 JP JP2022126880A patent/JP7434456B2/ja active Active
- 2022-11-08 AU AU2022268294A patent/AU2022268294B2/en active Active
-
2023
- 2023-02-03 US US18/105,316 patent/US20230220061A1/en active Pending
-
2024
- 2024-02-07 JP JP2024016902A patent/JP2024054237A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202000478B (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies | |
| ZA201807389B (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| HK1246179A1 (zh) | 治療視網膜疾病的方法 | |
| ZA201602839B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| EP2986306A4 (en) | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING | |
| HK1226308A1 (zh) | 使用白細胞介素-10治療疾病和病症的方法 | |
| IL264070A (en) | Methods and preparations for the treatment of disorders and diseases involving rdh12 | |
| PT3192524T (pt) | Preparação de hgf adequada para tratamento de distúrbios neurológicos | |
| HK1258994A1 (zh) | 用於疾病治療的方法 | |
| ZA201807390B (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| EP3523333C0 (en) | ANTI-CEACAM6 ANTIBODIES AND METHODS OF USE THEREOF | |
| EP3341012A4 (en) | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING | |
| HK1245671A1 (zh) | 使用白細胞介素-10治療疾病和病症的方法 | |
| EP2958561A4 (en) | METHODS OF TREATING DISEASES AND OPHTHALMIC DISORDERS | |
| EP3534932C0 (en) | TREATMENT OF DISEASES RELATED TO IGFB3 AND ITS RECEPTOR | |
| IL265971B (en) | Therapeutic materials and methods for their production | |
| EP3400067A4 (en) | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING | |
| GB201709651D0 (en) | Therapeutic parasite preparaton and methods of making and using |